Hangzhou Apextide Biopharmaceutical Technology Co., Ltd. (Apextide) is a subsidiary of Sinopep-Allsino Biopharmaceutical, located in Hangzhou Medical Port, Qiantang (New) District, Hangzhou. As Sinopep-Allsino Biopharmaceutical's strategic layout in the peptide and oligonucleotide CDMO field, the company has continuously increased R&D investment since its establishment, building a full-chain service system of "drug discovery—process development—commercial production." In 2025, it successfully passed an on-site inspection by the U.S. FDA, and its pharmaceutical production quality system has been recognized by an authoritative international regulatory agency. R&D personnel account for more than half of the company's staff, with master's and doctoral degree holders making up over 60%, and R&D expenses have accounted for 27% of investment in the past three years.
Products and Services
The company is deeply engaged in the small molecule, peptide, and oligonucleotide drug fields, providing global innovative pharmaceutical companies with one-stop CDMO services from preclinical research to commercial production, covering process development, clinical batch GMP production, analytical method development and quality research, regulatory submission support, and other stages. It has a forward-looking layout in the customized production of core raw materials such as weight-loss peptide drugs and small nucleic acid drugs. The company's Hangzhou Xiasha production base has achieved hundred-kilogram-scale oligonucleotide capacity. In 2025, the DMF for the raw material drug of the blockbuster oligonucleotide product Inclisiran submitted by the company received a receipt from the U.S. FDA, and it is expected to become the world's first company to submit a DMF for this product.
Honors and Qualifications
In 2025, the company was successfully selected for the second batch of Zhejiang Province specialized, refined, distinctive and innovative (SRDI) small and medium-sized enterprises in 2025; recognized by the Zhejiang Provincial Department of Economy and Information Technology, it was rated as a "Zhejiang Provincial Enterprise Research Institute" for 2025; it was selected for the "2025 Hangzhou Enterprise Technology Center Recognition List" released by the Hangzhou Municipal Bureau of Economy and Information Technology, making it the * selected enterprise in that year focused on the peptide and oligonucleotide CDMO direction; it had previously also been awarded qualifications such as Hangzhou Enterprise R&D Center and Qiantang District Eagle Enterprise. From October to November 2024, the company underwent a five-day on-site inspection by the U.S. FDA and in February 2025 received the inspection report confirming successful passage, with its quality management system meeting the FDA's strict cGMP requirements.
Corporate Culture
The company upholds Sinopep-Allsino Biopharmaceutical's strategic orientation of "leading in time, leading in technology," has long adhered to innovative R&D, deeply cultivated segmented markets, and developed distinctive pharmaceutical products. It adheres to a differentiated competition strategy, takes "specialized, refined, distinctive and innovative" as its development core, continuously increases R&D investment, strengthens talent training, builds technological advantages, and contributes to the innovative development of biomedicine.
(This introduction was intelligently generated by DeepSeek AI and is for reference only.)
What does Hangzhou Apextide Biopharmaceutical Technology Co., Ltd. require? Who is Hangzhou Apextide Biopharmaceutical Technology Co., Ltd. hiring? recruitment: 其他(研发和技术类)占比最多占60%,其次是科研类占60%. What education can get in at ? 硕士占比最多占80%,其次是本科占20%. High education required at ? 硕士占80%. Work experience required at ? 3-5年占比最多占40%,其次是1-3年占30%. Where are the job locations at ? 杭州占比最多占100%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows